FP
RUBY

Flagship Pioneering’s Rubius Therapeutics, Inc RUBY Stock Holding History

Flagship Pioneering’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-38,506,526
Closed -$6.55M – 12
2022
Q4 		$6.55M Hold
38,506,526
– – 0.21% 9
2022
Q3 		$16.6M Hold
38,506,526
– – 0.7% 9
2022
Q2 		$32.7M Hold
38,506,526
– – 1.23% 9
2022
Q1 		$212M Hold
38,506,526
– – 4.98% 3
2021
Q4 		$373M Hold
38,506,526
– – 5.76% 3
2021
Q3 		$688M Hold
38,506,526
– – 7.21% 3
2021
Q2 		$940M Hold
38,506,526
– – 12.01% 2
2021
Q1 		$1.02B Buy
38,506,526
+210,000
+0.5% +$3.07M 16.34% 3
2020
Q4 		$291M Hold
38,296,526
– – 5.29% 4
2020
Q3 		$192M Hold
38,296,526
– – 5.3% 5
2020
Q2 		$229M Hold
38,296,526
– – 6.65% 2
2020
Q1 		$170M Hold
38,296,526
– – 7.99% 2
2019
Q4 		$364M Hold
38,296,526
– – 20.34% 2
2019
Q3 		$301M Hold
38,296,526
– – 16.45% 2
2019
Q2 		$602M Hold
38,296,526
– – 26.07% 2
2019
Q1 		$693M Hold
38,296,526
– – 26.23% 2
2018
Q4 		$616M Hold
38,296,526
– – 30.07% 2
2018
Q3 		$919M Buy
+38,296,526
New +$876M 60.75% 1

Other funds holding RUBY

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Flagship Pioneering's RUBY Position: Q1 2023 in Review

Flagship Pioneering sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 38,506,526 shares — an estimated $6.55M sold.

Flagship Pioneering first reported a position in RUBY in Q3 2018 and held it in 18 quarters. The position peaked at $1.02B in Q1 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Flagship Pioneering reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Flagship Pioneering sold 38,506,526 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $6.55M.
  • Flagship Pioneering first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 18 quarters.
  • Flagship Pioneering's Rubius Therapeutics, Inc position peaked at $1.02B in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Flagship Pioneering's 13F filing for Q1 2023, filed 15 May 2023.